Lantus a Suitable Option for Type 1 Tykes


By: Daniel Trecroci

“The use of flexible multiple daily insulin [FMDI] therapy with glargine [Lantus] among preschool-aged children with type 1 diabetes mellitus was associated with improved overall glycemic control and decreased frequency of severe hypoglycemia.”

This is the opinion of Wisconsin researchers, who suggest that FMDI regimens of pre-meal Humalog and bedtime Lantus may be a feasible therapeutic alternative to multiple daily injection treatment for preschool-aged children with type 1. They note, however, that excess body weight status “appeared to preclude a desirable therapeutic response in this group of patients.”

Data were collected over a two-year period from 35 patients with an average age of 4.8 years. The patients had all received multiple daily injection insulin therapy for one year before being transitioned to an FMDI regimen.

Overall blood glucose control improved after transition to FMDI therapy; however, A1C levels improved only among normal-weight subjects and not among overweight subjects.

In addition, the overall rate of severe hypoglycemia was significantly decreased with the FMDI regimen, but only for normal-weight children.

Pediatrics, May 2005



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.